N4 Pharma (N4P) Competitors GBX 0.55 +0.03 (+4.76%) (As of 12/20/2024 09:50 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitors N4P vs. RGT, HELD, HLN, HIK, HCM, INDV, AMYT, AGY, APH, and BXPShould you be buying N4 Pharma stock or one of its competitors? The main competitors of N4 Pharma include Argent BioPharma (RGT), Hellenic Dynamics (HELD), Haleon (HLN), Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), and Beximco Pharmaceuticals (BXP). These companies are all part of the "drug manufacturers - specialty & generic" industry. N4 Pharma vs. Argent BioPharma Hellenic Dynamics Haleon Hikma Pharmaceuticals HUTCHMED Indivior Amryt Pharma Allergy Therapeutics Alliance Pharma Beximco Pharmaceuticals N4 Pharma (LON:N4P) and Argent BioPharma (LON:RGT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment. Does the MarketBeat Community prefer N4P or RGT? N4 Pharma received 103 more outperform votes than Argent BioPharma when rated by MarketBeat users. CompanyUnderperformOutperformN4 PharmaOutperform Votes10365.61% Underperform Votes5434.39% Argent BioPharmaN/AN/A Does the media favor N4P or RGT? In the previous week, N4 Pharma's average media sentiment score of 0.00 equaled Argent BioPharma'saverage media sentiment score. Company Overall Sentiment N4 Pharma Neutral Argent BioPharma Neutral Which has more volatility & risk, N4P or RGT? N4 Pharma has a beta of -0.37, indicating that its stock price is 137% less volatile than the S&P 500. Comparatively, Argent BioPharma has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Do institutionals & insiders hold more shares of N4P or RGT? 1.1% of Argent BioPharma shares are owned by institutional investors. 18.0% of N4 Pharma shares are owned by company insiders. Comparatively, 17.8% of Argent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is N4P or RGT more profitable? Argent BioPharma's return on equity of 0.00% beat N4 Pharma's return on equity.Company Net Margins Return on Equity Return on Assets N4 PharmaN/A -82.39% -56.00% Argent BioPharma N/A N/A -108.57% Which has higher valuation & earnings, N4P or RGT? N4 Pharma has higher revenue and earnings than Argent BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioN4 Pharma£23.52K92.30-£1.08MN/AN/AArgent BioPharmaN/AN/A-£17.53M-£0.24-23.67 SummaryN4 Pharma beats Argent BioPharma on 5 of the 9 factors compared between the two stocks. Ad ProsperityPubCrypto’s hidden gem + greatest crypto bull run in history = $$$?You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.Click Here to get the full details about Crypto’s Hidden Gem Get N4 Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart N4P vs. The Competition Export to ExcelMetricN4 PharmaDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£2.17M£1.17B£5.14B£1.91BDividend Yield3.12%3.04%5.09%5.45%P/E Ratio-55.00131.2390.051,867.09Price / Sales92.301,981.001,116.25393,302.55Price / Cash2.2510.2543.1028.64Price / BookN/A3.084.782.81Net Income-£1.08M£152.21M£120.31M£155.77M7 Day Performance-8.33%-0.48%-1.92%-2.02%1 Month Performance-21.43%-1.88%13.65%21.67%1 Year Performance-40.48%98.32%28.34%29.76% N4 Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)N4PN4 PharmaN/AGBX 0.55+4.8%N/A-38.9%£2.17M£23,524.00-55.005Gap UpRGTArgent BioPharmaN/AGBX 6.50-7.1%N/AN/A£3.49MN/A-27.08N/AGap DownHigh Trading VolumeHELDHellenic DynamicsN/AGBX 0.95flatN/AN/A£1.40MN/A0.00N/AHLNHaleon0.6406 of 5 starsN/AGBX 415+∞+18.8%£34.43B£11.26B3,165.0025,408HIKHikma Pharmaceuticals1.5471 of 5 starsGBX 1,938+0.2%GBX 2,383.33+23.0%+9.2%£4.30B£3.02B2,981.549,100News CoverageHCMHUTCHMEDN/AGBX 239-3.2%N/A-11.7%£2.04B£610.81M-5,975.001,760INDVIndivior2.4989 of 5 starsGBX 950+4.6%GBX 1,500+57.9%-21.9%£1.22B£1.15B-1,187.501,000Analyst ForecastAMYTAmryt PharmaN/AGBX 143-11.7%N/AN/A£457.11M£210.24M-4.33290Gap DownAGYAllergy TherapeuticsN/AGBX 6.40+3.2%N/A+220.0%£305.28M£53.26M-106.67612APHAlliance Pharma3.3054 of 5 starsGBX 48.40+0.4%GBX 60+24.0%+17.3%£261.64M£183.15M-806.6791,000News CoveragePositive NewsBXPBeximco PharmaceuticalsN/AGBX 36.50flatN/A-14.6%£162.83M£43.08B456.255,500News Coverage Related Companies and Tools Related Companies Argent BioPharma Alternatives Hellenic Dynamics Alternatives Haleon Alternatives Hikma Pharmaceuticals Alternatives HUTCHMED Alternatives Indivior Alternatives Amryt Pharma Alternatives Allergy Therapeutics Alternatives Alliance Pharma Alternatives Beximco Pharmaceuticals Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:N4P) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding N4 Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share N4 Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.